Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of cannabidiol as treatment for early psychosis

Trial Profile

A study of cannabidiol as treatment for early psychosis

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Psychotic disorders
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 17 Dec 2018 According to an INSYS Therapeutics, Inc. media release, this study is expected to be opened in the first half of 2019.
  • 15 Sep 2018 New trial record
  • 04 Sep 2018 According to an INSYS Therapeutics media release, this trial is being conducted under collaboration with the University of California (UC) San Diego School of Medicines Center for Medicinal Cannabis Research (CMCR) and is expected to commence in 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top